Today, we sit down with Dr. Talal Hilal, a physician who is originally from Syria. He completed his medical school training at the Royal College of Surgeons in Ireland (RCSI) campus in Bahrain in 2012. He applied for residency training as an IMG in 2013. He did his residency in Internal Medicine at the University of Kentucky, and graduated in 2016. At the time of this interview, he was chief fellow in the Hematology/Oncology fellowship at Mayo Clinic in Phoenix, AZ and graduated in the summer of 2019. His clinical interests are hematology (specifically lymphoproliferative disorders), application of evidence-based medicine in clinical practice, and pragmatic trial designs.
1.58 Magic Mouthwash with Dr. Arjun Gupta & Precision Oncology with Dr. Talal Hilal
This week we discuss three paired papers on precision oncology published in Nature Medicine and then, later in the episode, go in-depth on the implications of these negative studies with Dr. Talal Hilal of the Mayo Clinic. We also discuss the use of magic mouthwash for oral mucositis with Plenary Session fan, Dr. Arjun Gupta of Johns Hopkins University. WINTHER: doi.org/10.1038/s41591-019-0424-4TARGET: doi.org/10.1038/s41591-019-0380-zI-PREDICT: doi.org/10.1038/s41591-019-0407-5Magic mouthwash: doi.org/10.1001/jamainternmed.2018.6223Back us on Patreon! www.patreon.com/plenarysession
1.57 BONUS! Control Arm Quality in RCTs Leading to Anticancer Drug FDA Approval with Dr. Talal Hilal
In this BONUS episode, we interview Dr. Talal Hilal of the Mayo Clinic on his paper that was published today in JAMA Oncology, titled "Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration". Control Arm Quality: doi.org/10.1001/jamaoncol.2019.0167Back us on Patreon! www.patreon.com/plenarysession
1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527Reporting harms: doi.org/10.1136/bmj.k4383
1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu
Listen in for a breakdown of the good and the bad of KEYNOTE-189(trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.